^
Association details:
| Biomarker: | BRAF G466V + KIT K509Q |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1968p - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib
Published date:
09/14/2020
Excerpt:
The patient that had a concurrent BRAF p.(G466V) and KIT p.(K509Q) mutations had a stable disease for only 3 months
